0.05
-6.00%
Close of 9 Nov 2026, in HKD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Extrawell Pharmaceutical Holdings
Its shares trade on HKEX under the ticker 858.HK. It has been listed since 10 March 1999. In the fiscal year to 31 March 2025, it reported revenue of HK$55.4m and net income of HK$222.6m. At that date it held total assets of HK$1.53bn and shareholders' equity of HK$1.33bn.
Extrawell Pharmaceutical Holdings Ltd. engages in the marketing and distribution of pharmaceutical products. The company employs 181 full-time employees The firm operates its business through three segments. The Manufacturing segment is engaged in the development, manufacture and sales of pharmaceutical products. Its self-produced products include Transfer Factor Oral Solution, Wisk, ZhouBang and others. The Trading segment is engaged in the promotion and distribution of imported pharmaceuticals. Its imported products include Millibar and Skin Cap. The Gene Development segment is engaged in the commercial development and research, development of gene-related technologies.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 10 Mar 1999
- Employees
- 181
- Website
- extrawell.com.hk ↗
Leadership
Pay as last reported
- Dr. Yi XieExecutive Chairman of the Board, Chief Executive Officer, since 2001HK$1.4m
- Mr. Yong ChengDeputy Chief Executive Officer, Executive Director, since 2013HK$713,000
- Ms. Sau Kuen WongExecutive Director, Company Secretary, since 2008HK$940,000
- Dr. Yi GuoExecutive Director, since 2023
- Dr. Yi LouExecutive Director, since 2008HK$557,000
- Mr. Youlu GongGeneral Manager of Changchun Extrawell Pharmaceutical Co., Ltd.
- Mr. Huang WendaFinancial Controller of CEP and JCEP
- Ms. Hong WuGroup Senior Finance Manager
- Mr. Lin Hu FangIndependent Non-Executive DirectorHK$70,000
- Ms. Song JinIndependent Non-Executive DirectorHK$70,000
- Dr. Zeng LiIndependent Non-Executive Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Company employs 181 full-time employees
- Operates through three business segments: Manufacturing, Trading, and Gene Development
- Owns self-produced pharmaceutical products including Transfer Factor Oral Solution, Wisk, and ZhouBang
Weaknesses
- City location is unknown
- No specific details on financial performance provided
- Source description is labeled as untrusted facts
Opportunities
- Potential growth in gene-related technology development
- Expansion of imported pharmaceutical distribution through Trading segment
- Increased market presence for self-produced products like Transfer Factor Oral Solution
Threats
- Reliance on untrusted source for factual information
- Limited public information on company operations
- No mention of competitive landscape or market challenges
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.